AGN Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands andbest-in-class products primarily focused on four key therapeutic areas including medical aesthetics, eye care, central nervous system and gastroenterology. As part of its approach to delivering innovation for better patient care, Allergan has built one of the broadest pharmaceutical and device research and development pipelines in the industry.
Company profile
Ticker
AGN
Exchange
Website
CEO
Brenton L. Saunders
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Actavis Ltd, Actavis plc
SEC CIK
Corporate docs
AGN stock data
()
Calendar
7 May 20
25 Sep 20
31 Dec 20
News
Recent insider trades
| Date | Owner | Security | Transaction | Code | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|
| 8 May 20 | Coughlin Christopher J | Ordinary Shares, par value $0.0001 | Sale back to company | Dispose D | No | 0 | 16,532 | 0 | 0 |
| 8 May 20 | Coughlin Christopher J | Ordinary Shares, par value $0.0001 | Sale back to company | Dispose D | No | 0 | 9,538 | 0 | 16,542 |
| 8 May 20 | Coughlin Christopher J | Ordinary Shares, par value $0.0001 | Sale back to company | Dispose D | No | 0 | 471 | 0 | 26,080 |
| 8 May 20 | Coughlin Christopher J | Stock Options Ordinary Shares | Sale back to company | Dispose D | No | 70.79 | 9,446 | 668.68K | 0 |
| 8 May 20 | Coughlin Christopher J | Stock Options Ordinary Shares | Sale back to company | Dispose D | No | 73.14 | 3,691 | 269.96K | 0 |
| 8 May 20 | Coughlin Christopher J | Stock Options Ordinary Shares | Sale back to company | Dispose D | No | 90.22 | 2,790 | 251.71K | 0 |
| 8 May 20 | William Meury | RSU | Sale back to company | Dispose D | No | 0 | 25,201 | 0 | 0 |
| 8 May 20 | William Meury | Ordinary Shares, par value $0.0001 | Sale back to company | Dispose D | No | 0 | 7,434 | 0 | 0 |
| 8 May 20 | William Meury | Performance Stock Units Ordinary Shares | Sale back to company | Dispose D | No | 0 | 26,506 | 0 | 0 |
| 8 May 20 | William Meury | Stock Options Ordinary Shares | Sale back to company | Dispose D | No | 196.16 | 12,304 | 2.41M | 0 |
Institutional ownership Q2 2020
0.1% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 9 |
| Opened positions | 1 |
| Closed positions | 846 |
| Increased positions | 2 |
| Reduced positions | 3 |
13F shares |
Current |
|---|---|
| Total value | 22.42M |
| Total shares | 272.23K |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
Largest owners |
Shares | Value |
|---|---|---|
| Ashburton | 195.5K | $15.12M |
| JDC-JSC | 35.07K | $85K |
| Cerebellum GP | 20.26K | $3.31M |
| Advisor Partners | 9.28K | $1.64M |
| Everence Capital Management | 7.1K | $1.37M |
| Barings | 4.87K | $862K |
| Valeo Financial Advisors | 145 | $28K |
| Orion Portfolio Solutions | 4 | $1K |
| IFP Advisors | 0 | $0 |
Financial report summary
?Competition
Akorn • TherapeuticsMD • Amgen • Insite Vision • Medicis Pharmaceutical • Hologic • Veru • Vivus • Cynosure • Uroplasty
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
New words:
alpha, API, argument, Asia, AstraZeneca, autoimmune, behavior, biodegradable, broadest, built, buyer, Cadila, certainty, chain, composition, confirm, confirming, contamination, continent, Coolsculpting, CoolTone, Cream, cystic, declare, deliver, detailing, discontinuation, discontinued, distancing, Durysta, electronic, enrolling, environment, enzyme, Esthetique, evolve, exocrine, experienced, Gedeon, genericization, glaucoma, globe, half, home, hypertension, inability, indirectly, inhibitor, innovation, insufficiency, intracameral, intraocular, IOP, Ireland, Lab, Lazeo, LIBOR, lifetime, local, logistical, losing, medial, minute, mitigate, Nestle, OAG, ocular, OHT, outbreak, Pacific, pancreatic, pandemic, patient, pressure, rebate, recession, recovery, relationship, remotely, reply, Richter, satisfaction, Science, shelter, spent, spread, strain, susceptible, suspended, temporarily, Ubrelvy, unemployment, Viokace, Vital
Removed:
absence, acceleration, acid, add, adjunctive, advancement, affirming, Akorn, Akron, Apotex, appellate, applied, Argentum, asserting, authorize, automatically, back, binding, BioMed, Biomedical, Body, bound, buy, calculate, calculated, capitalized, capitalizing, Center, centralized, certiorari, chosen, clarify, cloud, collateralization, collateralized, commonly, computing, concurrently, Contouring, contractually, conversion, correct, corrected, Corrupt, cumulative, delaying, Delzicol, denial, denying, Depressive, dermatology, determining, Deva, disgorgement, Disorder, dozen, Easement, enablement, enacted, enforceable, Envy, equaled, equipment, equitable, error, established, estate, Europe, exemption, exercised, expedient, explicitly, Famy, fiscal, fleet, fourth, Framework, gamma, GILTI, ground, Harbor, HD, higher, hosted, immunity, implementation, implicit, implicitly, improper, incorrectly, India, Influenced, InnoPharma, institute, instrument, intent, invalidity, inventorship, issuing, joinder, LA, land, lease, leasing, Legacy, legally, lessee, lessor, Lidoderm, LifeCell, limit, Low, mandatorily, mandatory, MDD, modified, modify, noncancelable, notification, offsetting, older, opening, option, orphan, ownership, package, pattern, Pennsylvania, pension, permission, pertaining, Pharmacal, pivotal, plant, Plastic, postretirement, practical, preferred, prepaid, preventing, privately, pronouncement, prospectively, purpose, qualify, Racketeer, rapastinel, rating, reaching, real, receptor, reclassification, reclassify, recognition, redeemed, refinancing, released, remove, renew, renewal, rental, Replacement, represented, requiring, residual, restitution, resurfacing, retinoic, retired, retrospective, retrospectively, revaluation, reversing, RORyt, ROU, SA, scaling, shortened, skin, Slayback, software, sovereign, standalone, statutory, stranded, substantive, substitute, Subtopic, suit, supplier, Surgery, suspension, Targeted, Taxed, TCJA, terminate, Therapy, threshold, topline, treble, tribal, TWi, Ubrogepant, unrelated, updated, USD, vendor, VI, Vitae, withdraw, withdrew, writ
Financial reports
10-Q
2020 Q1
Quarterly report
7 May 20
10-K/A
2019 FY
Annual report (amended)
29 Apr 20
10-K
2019 FY
Annual report
18 Feb 20
10-Q
2019 Q3
Quarterly report
5 Nov 19
10-Q
2019 Q2
Quarterly report
8 Aug 19
10-Q
2019 Q1
Quarterly report
7 May 19
10-K
2018 FY
Annual report
15 Feb 19
10-Q
2018 Q3
Quarterly report
31 Oct 18
10-Q
2018 Q2
Quarterly report
3 Aug 18
10-Q/A
2018 Q1
Quarterly report (amended)
25 May 18
Current reports
8-K
Material Modifications to Rights of Security Holders
14 May 20
8-K
AbbVie Inc. Completes Acquisition of Allergan plc
8 May 20
8-K
Announcement relating to the outcome of the Court Sanction Hearing
6 May 20
8-K
Temporary Suspension of Trading Under Registrant's Employee Benefit Plans
21 Apr 20
8-K
AbbVie and Allergan Sign Consent Decree Agreement with Federal Trade Commission Staff on Pending Transaction
18 Mar 20
8-K
AbbVie and Allergan Receive Final European Approval to Close Pending Transaction
3 Mar 20
8-K
Allergan Reports Fourth Quarter and Full-Year 2019 Financial Results
10 Feb 20
8-K
AbbVie and Allergan Announce Agreements to Divest Brazikumab and Zenpep
27 Jan 20
8-K
Third Quarter 2019 Financial Results—Frequently Asked Questions
5 Nov 19
8-K
Allergan Reports Third Quarter 2019 Financial Results
5 Nov 19
Registration and prospectus
15-12B
Securities registration termination
21 May 20
POS AM
Prospectus update (post-effective amendment)
14 May 20
POS AM
Prospectus update (post-effective amendment)
14 May 20
POS AM
Prospectus update (post-effective amendment)
14 May 20
POS AM
Prospectus update (post-effective amendment)
14 May 20
S-8 POS
Registration of securities for employees (post-effective amendment)
14 May 20
S-8 POS
Registration of securities for employees (post-effective amendment)
14 May 20
S-8 POS
Registration of securities for employees (post-effective amendment)
14 May 20
S-8 POS
Registration of securities for employees (post-effective amendment)
14 May 20
S-8 POS
Registration of securities for employees (post-effective amendment)
14 May 20
Proxies
DEFA14A
Additional proxy soliciting materials
3 Oct 19
DEFA14A
Additional proxy soliciting materials
27 Sep 19
DEFM14A
Proxy related to merger
16 Sep 19
DEFA14A
Additional proxy soliciting materials
11 Sep 19
PREM14A
Preliminary proxy related to merger
12 Aug 19
DEFA14A
Additional proxy soliciting materials
12 Jul 19
DEFA14A
Additional proxy soliciting materials
8 Jul 19
DEFA14A
Additional proxy soliciting materials
2 Jul 19
DEFA14A
Additional proxy soliciting materials
28 Jun 19
DEFA14A
Additional proxy soliciting materials
28 Jun 19
Other
EFFECT
Notice of effectiveness
19 May 20
EFFECT
Notice of effectiveness
19 May 20
EFFECT
Notice of effectiveness
19 May 20
EFFECT
Notice of effectiveness
19 May 20
SD
Conflict minerals disclosure
23 May 19
SD
Conflict minerals disclosure
31 May 18
SD
Conflict minerals disclosure
31 May 17
UPLOAD
Letter from SEC
23 Feb 17
CORRESP
Correspondence with SEC
14 Feb 17
UPLOAD
Letter from SEC
7 Feb 17
Ownership
4
Allergan / Nesli Basgoz ownership change
12 May 20
4
Allergan / Joseph H Boccuzi ownership change
12 May 20
4
Allergan / ROBERT J HUGIN ownership change
12 May 20
4
Allergan / CHRIS W BODINE ownership change
12 May 20
4
Allergan / James DArecca ownership change
12 May 20
4
Allergan / Adriane M Brown ownership change
12 May 20
4
Allergan / A Robert D Bailey ownership change
12 May 20
4
Allergan / THOMAS C FREYMAN ownership change
12 May 20
4
Allergan / MATTHEW M WALSH ownership change
12 May 20
4
Allergan / CAROL ANTHONY DAVIDSON ownership change
12 May 20
Patents
APP
Utility
Soft Filled Prosthesis Shell with Discrete Fixation Surfaces
24 Sep 20
A method of augmenting or reconstructing a breast of a patient includes providing an implantable member and implanting the implantable member.
APP
Utility
Time Released Biodegradable or Bioerodible Microspheres or Microparticles Suspended In a Solidifying Depot-forming Injectable Drug Formulation
24 Sep 20
A composite drug delivery material may be injected into an eye of a human being or mammal to provide sustained delivery of the drug.
APP
Utility
Bicyclic Compound, Production and Use Thereof
24 Sep 20
Inventors: Mitsuru SHIRAISHI, Masanori BABA, Katsuji AIKAWA, Naoyuki KANZAKI, Masaki SETO, Yuji IIZAWA
GRANT
Utility
Suspension compositions of cyclosporin A for subconjunctival and periocular injection
22 Sep 20
The present disclosure relates to suspension formulations and systems for the treatment of ocular conditions.
GRANT
Utility
Non-irritating testosterone emulsions
22 Sep 20
Disclosed herein are emulsions comprising testosterone or related androgens, castor oil, cyclodextrin, Pemulen TR-2, Polyoxyl 40, and other ingredients.